These single-arm studies evaluated efficacy in relation to the proportion of tumor cells expressing PD-L1 with thresholds: 1%, 25%, 50%, 75%, etc. In addition to PD-L1, thresholds applied to multiple TME biomarkers have been proposed for prognostic subgroup classification10,21. The gene discussed is CD274; the disease is neoplasm.